Laureate Pharma gets access to Boehringer Ingelheim's technology for biologics production.
Boehringer Ingelheim (BI) has signed a preferred partnership agreement with Laureate Pharma giving Laureate's clients the benefit of BI's mammalian cell culture manufacturing technology platform for biopharmaceutical products.
Laureate will now offer its clients bioprocessing services that include: creation and development of production cell lines using Boehringer's BI HEX expression system; full-service process development and manufacture of early stage clinical supplies at Laureate's cGMP manufacturing facility in Princeton, NJ; and access to Boehringer's large-scale commercial production at its facility in Biberach, Germany.
The two companies will harmonise their bioprocessing methods to ensure seamless transfer of manufacturing activities from Laureate to Boehringer.
Acknowledging the advantage of a complete path from clinical-scale production, at Laureate, to large-scale commercial manufacturing, at Boehringer Ingelheim, Robert Broeze, president and chief executive officer of Laureate Pharma sees that, "working together, Laureate Pharma and Boehringer Ingelheim offer a comprehensive menu of manufacturing solutions in the U.S. and Europe."
Dr. Rolf G. Werner, senior vice president at BI's corporate division for biopharmaceuticals saw the stategic fit of BI's worldwide strategic manufacturing network with Laureate Pharma's stength in process development and clinical material supply. "Our process know-how allows state-of-the-art and time-to-clinic development at Laureate as well as smooth technology transfer to Boehringer Ingelheim's commercial manufacturing."
Keywords : Deals & Alliances, Boehringer-Ingelheim, Germany, Laureate Pharma, USA, Preferred partnership, mammalian cell culture technology, biologics, biopharmaceuticals, process development, commerical scale biomanufacturing, technology transfer, clinical trial
